Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
Lung cancer is a malignant tumor with the highest mortality in the world. The most common pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years, immunotherapy has brought about epoch-making changes in the treatment of NSCLC. In particular, immune checkpoint inhibito...
Enregistré dans:
Auteurs principaux: | Chuan HUANG, Xue YANG |
---|---|
Format: | article |
Langue: | ZH |
Publié: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ae484970d4ee4d4ab5327fcf84f9f91a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
par: Giustini N, et autres
Publié: (2021) -
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer
par: Huiqiu ZHANG, et autres
Publié: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
par: Fitzpatrick O, et autres
Publié: (2021) -
Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
par: Takuma Imakita, et autres
Publié: (2021) -
Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
par: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et autres
Publié: (2021)